Loading...

C-MER Eye Care Holdings

SEHK:3309
Snowflake Description

High growth potential with excellent balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
3309
SEHK
HK$9B
Market Cap
  1. Home
  2. HK
  3. Healthcare
Company description

C-MER Eye Care Holdings Limited, an investment holding company, provides ophthalmic services under the C-MER Dennis Lam brand name in Hong Kong and the People’s Republic of China. The last earnings update was 172 days ago. More info.


Add to Portfolio Compare Print Invest
  • C-MER Eye Care Holdings has significant price volatility in the past 3 months.
3309 Share Price and Events

Value

 Is C-MER Eye Care Holdings undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of C-MER Eye Care Holdings to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for C-MER Eye Care Holdings.

SEHK:3309 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 2 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8.4%
Perpetual Growth Rate 10-Year HK Government Bond Rate 2.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for SEHK:3309
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year HK Govt Bond Rate 2.2%
Equity Risk Premium S&P Global 7.8%
Healthcare Unlevered Beta Simply Wall St/ S&P Global 0.59
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.585 (1 + (1- 25%) (0.1%))
0.585
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.8
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.2% + (0.8 * 7.8%)
8.44%

Discounted Cash Flow Calculation for SEHK:3309 using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for C-MER Eye Care Holdings is arrived at by discounting future cash flows to their present value using the 2 stage method. We use analyst's estimates of cash flows going forward 5 years for the 1st stage, the 2nd stage assumes the company grows at a stable rate into perpetuity.

SEHK:3309 DCF 1st Stage: Next 5 year cash flow forecast
2018 2019 2020 2021 2022
Levered FCF (HKD, Millions) 69.00 136.00 160.48 187.76 217.80
Source Analyst x1 Analyst x1 Extrapolated @ (18%, capped from 20.34%) Extrapolated @ (17%, capped from 20.34%) Extrapolated @ (16%, capped from 20.34%)
Present Value
Discounted (@ 8.44%)
63.63 115.65 125.85 135.78 145.25
Present value of next 5 years cash flows HK$586
SEHK:3309 DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2022 × (1 + g) ÷ (Discount Rate – g)
= HK$218 × (1 + 2.2%) ÷ (8.44% – 2.2%)
HK$3,569
Present Value of Terminal Value = Terminal Value ÷ (1 + r)5
= HK$3,569 ÷ (1 + 8.44%)5
HK$2,380
SEHK:3309 Total Equity Value
Calculation Result
Total Equity Value = Present value of next 5 years cash flows + Terminal Value
= HK$586 + HK$2,380
HK$2,966
Equity Value per Share
(HKD)
= Total value / Shares Outstanding
= HK$2,966 / 1,030
HK$2.88
SEHK:3309 Discount to Share Price
Calculation Result
Value per share (HKD) From above. HK$2.88
Current discount Discount to share price of HK$8.69
= -1 x (HK$8.69 - HK$2.88) / HK$2.88
-201.6%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of C-MER Eye Care Holdings is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for C-MER Eye Care Holdings's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are C-MER Eye Care Holdings's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
SEHK:3309 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings () in HKD HK$0.05
SEHK:3309 Share Price ** SEHK (2018-06-20) in HKD HK$8.69
Hong Kong Healthcare Industry PE Ratio Median Figure of 25 Publicly-Listed Healthcare Companies 30.48x
Hong Kong Market PE Ratio Median Figure of 1,529 Publicly-Listed Companies 12.93x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of C-MER Eye Care Holdings.

SEHK:3309 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= SEHK:3309 Share Price ÷ EPS (both in HKD)

= 8.69 ÷ 0.05

166.6x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • C-MER Eye Care Holdings is overvalued based on earnings compared to the HK Healthcare industry average.
  • C-MER Eye Care Holdings is overvalued based on earnings compared to the Hong Kong market.
Price based on expected Growth
Does C-MER Eye Care Holdings's expected growth come at a high price?
Raw Data
SEHK:3309 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 166.6x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
49.8%per year
Hong Kong Healthcare Industry PEG Ratio Median Figure of 9 Publicly-Listed Healthcare Companies 1.09x
Hong Kong Market PEG Ratio Median Figure of 520 Publicly-Listed Companies 0.9x

*Line of best fit is calculated by linear regression .

SEHK:3309 PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 166.6x ÷ 49.8%

3.35x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • C-MER Eye Care Holdings is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on C-MER Eye Care Holdings's assets?
Raw Data
SEHK:3309 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings () in HKD HK$0.20
SEHK:3309 Share Price * SEHK (2018-06-20) in HKD HK$8.69
Hong Kong Healthcare Industry PB Ratio Median Figure of 40 Publicly-Listed Healthcare Companies 2.01x
Hong Kong Market PB Ratio Median Figure of 2,132 Publicly-Listed Companies 1.16x
SEHK:3309 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= SEHK:3309 Share Price ÷ Book Value per Share (both in HKD)

= 8.69 ÷ 0.20

44.3x

* Primary Listing of C-MER Eye Care Holdings.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • C-MER Eye Care Holdings is overvalued based on assets compared to the HK Healthcare industry average.
X
Value checks
We assess C-MER Eye Care Holdings's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Healthcare industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Healthcare industry average (and greater than 0)? (1 check)
  5. C-MER Eye Care Holdings has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is C-MER Eye Care Holdings expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
49.8%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is C-MER Eye Care Holdings expected to grow at an attractive rate?
  • C-MER Eye Care Holdings's earnings growth is expected to exceed the low risk savings rate of 2.2%.
Growth vs Market Checks
  • C-MER Eye Care Holdings's earnings growth is expected to exceed the Hong Kong market average.
  • C-MER Eye Care Holdings's revenue growth is expected to exceed the Hong Kong market average.
Annual Growth Rates Comparison
Raw Data
SEHK:3309 Future Growth Rates Data Sources
Data Point Source Value (per year)
SEHK:3309 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts 49.8%
SEHK:3309 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts 23.8%
Hong Kong Healthcare Industry Earnings Growth Rate Market Cap Weighted Average 15.7%
Hong Kong Healthcare Industry Revenue Growth Rate Market Cap Weighted Average 12.4%
Hong Kong Market Earnings Growth Rate Market Cap Weighted Average 15.2%
Hong Kong Market Revenue Growth Rate Market Cap Weighted Average 10%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
SEHK:3309 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (5 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in HKD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
SEHK:3309 Future Estimates Data
Date (Data in HKD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2020-12-31 645 1
2019-12-31 513 146 131 2
2018-12-31 396 119 103 1
SEHK:3309 Past Financials Data
Date (Data in HKD Millions) Revenue Cash Flow Net Income *
2017-12-31 311 65 40
2017-09-30 293 63 46
2017-06-30 274 60 52
2017-03-31 267 59 55
2016-12-31 249 53 47
2015-12-31 199 51 38

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • C-MER Eye Care Holdings's earnings are expected to grow significantly at over 20% yearly.
  • C-MER Eye Care Holdings's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
SEHK:3309 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (5 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from C-MER Eye Care Holdings Company Filings, last reported 5 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

SEHK:3309 Future Estimates Data
Date (Data in HKD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2020-12-31
2019-12-31
2018-12-31
SEHK:3309 Past Financials Data
Date (Data in HKD Millions) EPS *
2017-12-31 0.05
2017-09-30 0.06
2017-06-30 0.07
2017-03-31 0.08
2016-12-31 0.06
2015-12-31 0.05

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • C-MER Eye Care Holdings is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess C-MER Eye Care Holdings's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Hong Kong market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Hong Kong market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
C-MER Eye Care Holdings has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has C-MER Eye Care Holdings performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare C-MER Eye Care Holdings's growth in the last year to its industry (Healthcare).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • C-MER Eye Care Holdings's year on year earnings growth rate has been positive over the past 5 years, however the most recent earnings are below average.
  • C-MER Eye Care Holdings's 1-year earnings growth is negative, it can't be compared to the 5-year average.
  • C-MER Eye Care Holdings's 1-year earnings growth is negative, it can't be compared to the HK Healthcare industry average.
Earnings and Revenue History
C-MER Eye Care Holdings's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from C-MER Eye Care Holdings Company Filings, last reported 5 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

SEHK:3309 Past Revenue, Cash Flow and Net Income Data
Date (Data in HKD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2017-12-31 311.23 40.13 54.85
2017-09-30 292.51 45.90 48.31
2017-06-30 273.80 51.67 41.78
2017-03-31 266.54 54.53 40.55
2016-12-31 248.66 46.89 38.41
2015-12-31 198.85 38.36 31.15
2014-12-31 156.47 22.36 30.59

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • C-MER Eye Care Holdings has efficiently used shareholders’ funds last year (Return on Equity greater than 20%).
  • C-MER Eye Care Holdings used its assets more efficiently than the HK Healthcare industry average last year based on Return on Assets.
  • C-MER Eye Care Holdings's use of capital has not improved over the past 3 years (Return on Capital Employed).
X
Past performance checks
We assess C-MER Eye Care Holdings's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Healthcare industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
C-MER Eye Care Holdings has a total score of 3/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is C-MER Eye Care Holdings's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up C-MER Eye Care Holdings's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • C-MER Eye Care Holdings is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • C-MER Eye Care Holdings's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of C-MER Eye Care Holdings's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 12.3x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from C-MER Eye Care Holdings Company Filings, last reported 5 months ago.

SEHK:3309 Past Debt and Equity Data
Date (Data in HKD Millions) Total Equity Total Debt Cash & Short Term Investments
2017-12-31 157.42 8.95 78.03
2017-09-30 157.42 8.95 78.03
2017-06-30 234.91 42.54 202.86
2017-03-31 79.10 45.81 88.09
2016-12-31 63.43 39.37 70.99
2015-12-31 66.95 41.96 46.87
2014-12-31 30.81 54.62 29.20
  • C-MER Eye Care Holdings's level of debt (5.7%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if C-MER Eye Care Holdings's debt level has increased without past 5-year debt data.
  • Debt is well covered by operating cash flow (731.9%, greater than 20% of total debt).
  • C-MER Eye Care Holdings earns more interest than it pays, coverage of interest payments is not a concern.
X
Financial health checks
We assess C-MER Eye Care Holdings's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. C-MER Eye Care Holdings has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is C-MER Eye Care Holdings's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from C-MER Eye Care Holdings dividends.
If you bought HK$2,000 of C-MER Eye Care Holdings shares you are expected to receive HK$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate C-MER Eye Care Holdings's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate C-MER Eye Care Holdings's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
SEHK:3309 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Hong Kong Healthcare Industry Average Dividend Yield Market Cap Weighted Average of 16 Stocks 1.9%
Hong Kong Market Average Dividend Yield Market Cap Weighted Average of 983 Stocks 3%
Hong Kong Minimum Threshold Dividend Yield 10th Percentile 1%
Hong Kong Bottom 25% Dividend Yield 25th Percentile 1.8%
Hong Kong Top 25% Dividend Yield 75th Percentile 4.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

SEHK:3309 Future Dividends Estimate Data
Date (Data in HK$) Dividend per Share (annual) Avg. No. Analysts
2020-12-31
2019-12-31
2018-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as C-MER Eye Care Holdings has not reported any payouts.
  • Unable to verify if C-MER Eye Care Holdings's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of C-MER Eye Care Holdings's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as C-MER Eye Care Holdings has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess C-MER Eye Care Holdings's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can C-MER Eye Care Holdings afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. C-MER Eye Care Holdings has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of C-MER Eye Care Holdings's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
  • C-MER Eye Care Holdings has no CEO, or we have no data on them.
Management Team
Board of Directors
Recent Insider Trading
  • No 3 month insider trading information.
Who owns this company?
X
Management checks
We assess C-MER Eye Care Holdings's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap and profit (greater than 0.5% of the company's profit + 0.03% of market cap)? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. C-MER Eye Care Holdings has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

External News
Loading...
Simply Wall St News

C-MER Eye Care Holdings Limited (HKG:3309) Has Attractive Fundamentals, Here's Why

Building up an investment case requires looking at a stock holistically. … Today I've chosen to put the spotlight on C-MER Eye Care Holdings Limited (HKG:3309) due to its excellent fundamentals in more than one area.

Simply Wall St -

Should You Expect C-MER Eye Care Holdings Limited (HKG:3309) To Continue Delivering An ROE Of 25.49%?

See our latest analysis for C-MER Eye Care Holdings What you must know about ROE Return on Equity (ROE) weighs C-MER Eye Care Holdings’s profit against the level of its shareholders’ equity. … For now, let’s just look at the cost of equity number for C-MER Eye Care Holdings, which is 4.96%. … Since C-MER Eye Care Holdings’s return covers its cost in excess of 20.53%, its use of equity capital is efficient and likely to be sustainable.

Simply Wall St -

Stock Pick Of The Day: C-MER Eye Care Holdings Limited (HKG:3309)

There's no stopping the C-MER Eye Care Holdings Limited (SEHK:3309) growth train, with analysts forecasting high top-line growth in the near future. … Net income is expected to reach HK$103.00M over the next year, and over the next five years, earnings are predicted to grow at an annual rate of 49.76% on average, compared to the industry average growth of 17.52%. … 3309 has high near term liquidity, with short term assets (cash and other liquid assets) amply covering upcoming one-year liabilities, as well as long-term commitments.

Simply Wall St -

Did C-MER Eye Care Holdings Limited's (HKG:3309) Recent Earnings Growth Beat The Trend?

When C-MER Eye Care Holdings Limited (SEHK:3309) announced its most recent earnings (30 June 2017), I compared it against two factor: its historical earnings track record, and the performance of its industry peers on average. … See our latest analysis for C-MER Eye Care Holdings Did 3309's recent earnings growth beat the long-term trend and the industry? … For C-MER Eye Care Holdings, its most recent earnings (trailing twelve month) is HK$51.67M, which, relative to the prior year's level, has risen by 21.29%.

Simply Wall St -

Should You Sell C-MER Eye Care Holdings Limited (HKG:3309) At This PE Ratio?

Formula Price-Earnings Ratio = Price per share ÷ Earnings per share P/E Calculation for 3309 Price per share = HK$13.26 Earnings per share = HK$0.071 ∴ Price-Earnings Ratio = HK$13.26 ÷ HK$0.071 = 187.1x On its own, the P/E ratio doesn’t tell you much; however, it becomes extremely useful when you compare it with other similar companies. … We preferably want to compare the stock’s P/E ratio to the average of companies that have similar features to 3309, such as capital structure and profitability. … For example, if you are inadvertently comparing riskier firms with 3309, then 3309’s P/E would naturally be higher than its peers since investors would reward its lower risk with a higher price.

Simply Wall St -

Company Info

Map
Description

C-MER Eye Care Holdings Limited, an investment holding company, provides ophthalmic services under the C-MER Dennis Lam brand name in Hong Kong and the People’s Republic of China. The company operates eye and surgery centers, and satellite clinics that provide cataract and intraocular lens implant, refractive correction, corneal and external eye disease, glaucoma, vitreo-retinal disease, oculoplastic and orbital disease, and squint and pediatric ophthalmology services. It also sells vision aid and pharmaceutical products. The company was founded in 2012 and is headquartered in Central, Hong Kong. C-MER Eye Care Holdings Limited is a subsidiary of C-MER Group Limited.

Details
Name: C-MER Eye Care Holdings Limited
3309
Exchange: SEHK
Founded: 2012
HK$8,946,789,500
1,029,550,000
Website: http://www.cmereye.com
Address: C-MER Eye Care Holdings Limited
Central Building,
Suite 1535,
Central,
Hong Kong
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
SEHK 3309 Ordinary Shares The Stock Exchange of Hong Kong Ltd. HK HKD 15. Jan 2018
Number of employees
Current staff
Staff numbers
301
C-MER Eye Care Holdings employees.
Industry
Healthcare Services
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2018/06/21 12:05
End of day share price update: 2018/06/20 00:00
Last estimates confirmation: 2018/06/06
Last earnings update: 2017/12/31
Last annual earnings update: 2017/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.